THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Clinical trials for THERAPY-RELATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for THERAPY-RELATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New transplant strategy aims to tame tough blood cancers
Disease control OngoingThis study is testing a two-drug chemotherapy regimen followed by a donor stem cell transplant for adults with certain blood cancers that are in remission or at high risk. The goal is to see if this approach can better control the disease and prevent it from coming back after the…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo targets rare, Tough-to-Treat cancer caused by prior therapy
Disease control OngoingThis study is testing whether two drugs, venetoclax and azacitidine, work better together to treat a specific type of bone marrow cancer called therapy-related myelodysplastic syndrome (t-MDS). This cancer can develop after a person has received chemotherapy or radiation for a pr…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Smart cell transplant aims to cure blood cancers with fewer side effects
Disease control OngoingThis trial is comparing a new, engineered cell transplant called Orca-T against the standard transplant for people with advanced blood cancers like leukemia. The goal is to see if Orca-T can better control the cancer while reducing a serious complication called graft-versus-host …
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for tough blood cancers: testing a Two-Drug attack
Disease control OngoingThis study is testing a new combination of two drugs, venetoclax and azacitidine, for patients with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has come back or stopped responding to standard treatment. The first part of the study aims …
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC